Clinical Trials Logo
  1. Home
  2. Chronic Renal Failure
  3. NCT00608998
  4. Details
NCT00608998 Clinical Trial

Identification of Cardiovascular Risk Factors Linked to Renal Failure Progression

Chronic Renal Failure Clinical Trial

— Pre-HD  

Official title:
Vascular Risk Factors and Coronary Calcifications in Chronic Renal Failure Patients: Identification of Specific Factors Linked to Renal Failure Progression

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00608998
Other study ID # 7853
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 2007
Est. completion date October 2011

Study information
Verified date January 2008
Source University Hospital, Montpellier
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of this study is to appreciate the influence of renal failure progression on vasculopathy (coronary calcifications and left ventricular hypertrophy) and cardiovascular risk factors.

Description:

The aim of this study is to appreciate the relationship between: - extension of coronary calcifications and chronic renal failure progression - extension of coronary calcifications and levels of osteoprotegerin (bone disease marker) - cardiovascular risk factors and coronary calcifications - cardiovascular risk factors and existence of cardiovascular diseases

Recruitment information / eligibility
Status Completed
Enrollment 120
Est. completion date October 2011
Est. primary completion date October 2011
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - Patient who has signed the written consent form - Patient aged > 18 and < 90 years - Chronic renal failure defined by glomerular filtration rate (GFR) - group 1: GFR >90 mL/min with urinary biological abnormalities and GFR comprised between 90 and 60 mL/min - group 2: GFR comprised between 60 and 30 mL/min - group 3: GFR <30 mL/min but without dialysis therapy Exclusion Criteria: - Chronic renal failure patient requiring dialysis therapy

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
France Centre Hospitalier Universitaire Montpellier

Sponsors (2)
Lead Sponsor Collaborator
University Hospital, Montpellier Ministry of Health, France

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary description of osteoprotegerin levels according to chronic renal failure progression inclusion
Secondary calcium score description according to chronic renal failure progression inclusion
Secondary osteoprotegerin description according to calcium score inclusion
Secondary relationship between cardiovascular risk factors and calcium score inclusion
Secondary relationship between cardiovascular risk factors and cardiovascular disease inclusion
See also
  Status Clinical Trial Phase
Recruiting NCT02565459 - MSC and Kidney Transplant Tolerance (Phase A) Phase 1
Recruiting NCT02356419 - rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics Phase 1
Recruiting NCT01876017 - Safety and Efficacy of BMMNC in Patients With Chronic Renal Failure Phase 1/Phase 2
Withdrawn NCT03019159 - Assessment of a Follow-up With Tele-consulting for Patients With Renal Failure Under Peritoneal Dialysis N/A
Completed NCT02047006 - Dose-finding of Rivaroxaban in Hemodialysis Phase 4
Completed NCT01617824 - Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes Phase 4
Completed NCT00597753 - Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis Phase 3
Completed NCT00828776 - Pharmacodynamics and Non-Clinical Inferiority of Heparin Sodium (Cristália) Compared With the Product Liquemine (Roche) in Chronic Renal Failure Phase 2/Phase 3
Terminated NCT00372489 - Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD Phase 2
Completed NCT00379899 - ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis Phase 4
Completed NCT00228436 - Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients Phase 2
Completed NCT03772171 - Estimate for Dietary Intakes and Hemodialysis Patients
Recruiting NCT02586402 - Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis Phase 2
Completed NCT01879618 - Use Of Fragmin In Hemodialysis Phase 3
Not yet recruiting NCT01346215 - Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure Phase 3
Completed NCT01220843 - FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease Phase 3
Completed NCT01111630 - Study of Erythropoietin (EPO) Administration Schedule Phase 4
Completed NCT00742716 - Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease Phase 2
Completed NCT00598273 - Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis Phase 3
Completed NCT00597584 - Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis Phase 3